Results 201 to 210 of about 18,729 (264)

Endothelin Receptors and Receptor Antagonists

1998
Multiple receptor subtypes for endothelin have been identified in pharmacological studies both in vitro and in vivo. As can be evidenced in the study by Yanagisawa et al, at least two receptor subtypes may be responsible for the biphasic nature of the hemodynamic response to intravenous injection of ET-1: a transient hypotension followed by a sustained
Andrew S. Tasker, David M. Pollock
openaire   +1 more source

Role of endothelin and endothelin receptor antagonists in renal disease

European Journal of Clinical Investigation, 2006
AbstractEndothelin (ET)‐1 is a potent vasoconstrictor peptide with pro‐inflammatory, mitogenic, and pro‐fibrotic properties that is closely involved in both normal renal physiology and pathology. ET‐1 exerts a wide variety of biological effects, including constriction of cortical and medullary vessels, mesangial cell contraction, stimulation of ...
W, Neuhofer, D, Pittrow
openaire   +2 more sources

Endothelins and endothelin receptor antagonists: Binding to plasma proteins

Life Sciences, 1996
Endothelins (ET) are 21-amino acid peptides that bind to membrane receptors to initiate a wide range of pathophysiological effects. PD-156707, L-749329, Ro-470203, and A-127722 are potent non-peptide ET receptor antagonists developed recently. When tested in human and rat plasma, both ET-1 and -3 and the four aforementioned antagonists exhibited a high
J R, Wu-Wong, W J, Chiou, D J, Hoffman, M, Winn, T W, von Geldern, T J, Opgenorth   +5 more
openaire   +2 more sources

Endothelin Receptor Antagonists

2015
Endothelin-1 (ET-1) is a potent vasoconstrictor and mitogen that is secreted by the endothelium. Pulmonary vascular expression of endothelin is increased in pulmonary hypertension and plasma levels correlate with the severity of disease. Several endothelin receptor antagonists (ERAs) have been developed and are available for the treatment of pulmonary ...
Josanna Rodriguez-Lopez, Richard N. Channick   +1 more
openaire   +1 more source

Endothelin-Receptor Antagonists in Uremic Cardiomyopathy

Journal of Cardiovascular Pharmacology, 2000
Increased endothelin-1 (ET-1) levels were found in patients with chronic renal failure. These correlate with the severity of renal failure. Patients with elevated ET-1 concentrations show an increased cardiovascular mortality. The prevalence of severe left ventricular hypertrophy (LVH) is a very important factor for survival and morbidity in uremic ...
S C, Wolf, F, Gaschler, S, Brehm, M, Klaussner, K, Amann, T, Risler, B R, Brehm   +6 more
openaire   +2 more sources

The renoprotective potential of endothelin receptor antagonists

Expert Opinion on Investigational Drugs, 2000
The endothelin system has been identified as having a substantial role in renal failure, both acute and chronic. Beside its well characterised haemodynamic effects, its mitogenic and pro-fibrotic properties have gained increased interest in the pathophysiology of chronic renal failure.
T, Knoll, M, Schaub, R, Birck, C, Braun, K P, Juenemann, P, Rohmeiss   +5 more
openaire   +2 more sources

Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects.

Drug Metabolism And Disposition, 1999
The absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan was investigated in healthy male subjects by administration of 14C-labeled compound.
Cornelia Weber, Rodolfo Gasser, G. Hopfgartner   +2 more
semanticscholar   +1 more source

Endothelin Receptor Antagonists in Cancer Therapy

Cancer Investigation, 2007
Endothelins are a family of peptide compounds which exert regulatory control over cellular processes important for growth, survival, invasion, and angiogenesis. In particular, endothelin-1, acting primarily through the endothelin-A receptor, is implicated in the neoplastic growth of multiple tumor types.
Mihailo, Lalich, Douglas G, McNeel, George, Wilding, Glenn, Liu   +3 more
openaire   +2 more sources

[Endothelin receptor antagonist].

Nihon rinsho. Japanese journal of clinical medicine, 2009
Pulmonary arterial hypertension(PAH) is an uncommon disease characterised by a progressive increase in pulmonary vascular resistance. An imbalance between vasoconstrictor/vasodilator activities could be responsible for altered pulmonary vascular tone and structure. In PAH patients, endothelin are increased.
Takuya, Kishi, Kenji, Sunagawa
openaire   +1 more source

Heart failure and endothelin receptor antagonists

Trends in Pharmacological Sciences, 1999
Cardiac myocytes and vascular endothelial cells produce endothelin-1, which increases the contractility of cardiac muscles and of vascular smooth muscles. Endothelin-1 also exerts long-term effects, such as myocardial hypertrophy, and causes cellular injury in cardiac myocytes.
T, Miyauchi, K, Goto
openaire   +2 more sources